Biopharma Stock Updates - 12/10/20

Data Updates:

$BNTX (+3.66%) - Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine

https://biontechse.gcs-web.com/news-releases/news-release-details/pfizer-and-biontech-announce-publication-results-landmark-phase

$MRNA (+1.00%) - First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine

https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participants-dosed-phase-23-study-covid
 

$RGNX - (+2.83%) - Dosing Of First Patient In Phase II ALTITUDE™ Trial Of RGX-314 For The Treatment Of Diabetic Retinopathy Using Suprachoroidal Delivery

https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-announces-dosing-first-patient-phase-ii-altitudetm
 

$SPRO (-1.03%) - First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease

https://investors.sperotherapeutics.com/news-releases/news-release-details/spero-therapeutics-announces-first-patient-dosed-spr720-phase-2a
 

$TGTX (+22.28%) - Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis

https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-positive-topline-results-ultimate-i-ii

Financial:

$KALV (+0.50%) - Reports Second Fiscal Quarter Results

https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-reports-second-fiscal-quarter-results
 

$NLTX (+1.17%) - Submission of Investigational New Drug Application for NL-201 De Novo Protein Immunotherapy Candidate for Cancer

http://investor.neoleukin.com/news-releases/news-release-details/neoleukin-therapeutics-announces-submission-investigational-new
 

$PTGX (-11.37%) –Public offering of$100,000,000 of shares of its common stock

https://investors.protagonist-inc.com/news-releases/news-release-details/protagonist-therapeutics-inc-announces-proposed-public-offering